Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Jefferson Research
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Onyx Pharmaceuticals Inc Announces N. Anthony Coles, M.D. as Chairman of Board of Directors
Onyx Pharmaceuticals Inc announced that its Board of Directors has elected N. Anthony Coles, M.D., Chairman of the Board. Dr. Coles is currently President, Chief Executive Officer and a member of Onyx's Board. Paul Goddard, Ph.D., will continue to serve as Lead Independent Director of the Onyx Board.
Latest Developments for Onyx Pharmaceuticals Inc
- Onyx Pharmaceuticals Inc's Stivarga (regorafenib) Tablets Approved By U.S. FDA For Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic GIST
- Bayer AG's Bayer HealthCare Pharmaceuticals And Onyx Pharmaceuticals, Inc.'s Phase 3 DECISION Trial Of Nexavar (sorafenib) Meets Primary Endpoint
- Onyx Pharmaceuticals Inc Submits New Drug Application For Regorafenib For Treatment Of Gastrointestinal Stromal Tumors
- Onyx Pharmaceuticals, Inc., Bayer AG's HealthCare Pharmaceuticals And Astellas Pharma Inc Announce Tarceva To Nexavar Did Not Provide Additional Benefit To Patients
Latest Key Developments in Biotechnology
- Share this
- Link this
- Digg this
Follow Reuters